Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jul;19(7):415.
doi: 10.1038/s41575-022-00637-3.

CXCR2 inhibition in NASH-HCC

Eleni Kotsiliti  1
Affiliations
Comment

CXCR2 inhibition in NASH-HCC

Eleni Kotsiliti. Nat Rev Gastroenterol Hepatol. 2022 Jul.
No abstract available

PubMed Disclaimer

Comment on

  • CXCR2 inhibition enables NASH-HCC immunotherapy.
    Leslie J, Mackey JBG, Jamieson T, Ramon-Gil E, Drake TM, Fercoq F, Clark W, Gilroy K, Hedley A, Nixon C, Luli S, Laszczewska M, Pinyol R, Esteban-Fabró R, Willoughby CE, Haber PK, Andreu-Oller C, Rahbari M, Fan C, Pfister D, Raman S, Wilson N, Müller M, Collins A, Geh D, Fuller A, McDonald D, Hulme G, Filby A, Cortes-Lavaud X, Mohamed NE, Ford CA, Raffo Iraolagoitia XL, McFarlane AJ, McCain MV, Ridgway RA, Roberts EW, Barry ST, Graham GJ, Heikenwälder M, Reeves HL, Llovet JM, Carlin LM, Bird TG, Sansom OJ, Mann DA. Leslie J, et al. Gut. 2022 Apr 27;71(10):2093-106. doi: 10.1136/gutjnl-2021-326259. Online ahead of print. Gut. 2022. PMID: 35477863 Free PMC article.

References

Original article
    1. Leslie, J. et al. CXCR2 inhibition enables NASH-HCC immunotherapy. Gut https://doi.org/10.1136/gutjnl-2021-326259 (2022) - DOI - PubMed

MeSH terms

LinkOut - more resources